Evidence map›Paper›PMID 37338615›Full record

Trial reportJournal of neurology2023

Efficacy and safety of clonidine for the treatment of impulse control disorder in Parkinson's disease: a multicenter, parallel, randomised, double-blind, Phase 2b Clinical trial.

Chloé Laurencin, Noémie Timestit, Ana Marques, Domitille Dilly Duchez, Caroline Giordana, Sara Meoni, Marine Huddlestone, Teodor Danaila, Mathieu Anheim, Hélène Klinger and 10 more

Registry-linked trialOpen access · hybridAbstract readRandomized Controlled TrialMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Journal of neurology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03552068 (Study of Clonidine Efficacy for the Treatment of Impulse Control Disorders in Parkinson's Disease), which is not on this map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
3.1field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT03552068 phase2completednot on this map

Study of Clonidine Efficacy for the Treatment of Impulse Control Disorders in Parkinson's Disease: A Pilot Double Blind Randomized Trial

TypeinterventionalSponsorHospices Civils de LyonRan2019 to 2021Enrolled38ConditionsParkinson's Disease, Mpulse Control DisordersArmsplacebo, Clonidine
3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 15 citations in OpenAlex.

  1. Review
  2. Review
  3. The Noradrenergic Brain in Parkinson's Disease.Current neurology and neuroscience reports · 2026
    Review
  4. Review
  5. Behavioral disorders in Parkinson disease: current view.Journal of neural transmission (Vienna, Austria : 1996) · 2025
    Review
  6. Review
  7. Neuropsychiatric disorders in Parkinson's disease.Therapeutic advances in neurological disorders · 2025
    Review
  8. Review
  9. Review
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

20 authors at 8 institutions in 2 countries.

Chloé LaurencinDepartment of Neurology C, Expert Parkinson Centre, Hospices Civils de Lyon, Pierre Wertheimer Neurological Hospital, Hôpital Neurologique Pierre Wertheimer, Service de Neurologie C - Hospices Civils de Lyon, NS-Park/F-CRIN, 69677, Bron, France. chloe.laurencin@chu-lyon.fr.ORCID http://orcid.org/0000-0002-1516-5401
Noémie TimestitDepartment of Biostatistics, University Hospital of Lyon, Lyon, France.
Ana MarquesDepartment of Neurology, Clermont-Ferrand University Hospital, NS-Park/F-CRIN, Clermont-Ferrand, France.
Domitille Dilly DuchezDepartment of Neurology, University Hospital of Saint-Etienne, Saint-Etienne, France.
Caroline GiordanaDepartment of Neurology, University Hospital of Nice, NS-Park/F-CRIN, Nice, France.
Sara MeoniMovement Disorders Unit, Department of Neurology, University Hospital of Grenoble, NS-Park/F-CRIN, Grenoble, France.
Marine HuddlestoneDepartment of Neurology C, Expert Parkinson Centre, Hospices Civils de Lyon, Pierre Wertheimer Neurological Hospital, Hôpital Neurologique Pierre Wertheimer, Service de Neurologie C - Hospices Civils de Lyon, NS-Park/F-CRIN, 69677, Bron, France.
Teodor DanailaDepartment of Neurology C, Expert Parkinson Centre, Hospices Civils de Lyon, Pierre Wertheimer Neurological Hospital, Hôpital Neurologique Pierre Wertheimer, Service de Neurologie C - Hospices Civils de Lyon, NS-Park/F-CRIN, 69677, Bron, France.
Mathieu AnheimDepartment of Neurology, Strasbourg University Hospital, Strasbourg, France.
Hélène KlingerDepartment of Neurology C, Expert Parkinson Centre, Hospices Civils de Lyon, Pierre Wertheimer Neurological Hospital, Hôpital Neurologique Pierre Wertheimer, Service de Neurologie C - Hospices Civils de Lyon, NS-Park/F-CRIN, 69677, Bron, France.
Tiphaine VidalDepartment of Neurology, Clermont-Ferrand University Hospital, NS-Park/F-CRIN, Clermont-Ferrand, France.
Marion FatissonDepartment of Neurology, University Hospital of Saint-Etienne, Saint-Etienne, France.
Catherine CaireDepartment of Neurology C, Expert Parkinson Centre, Hospices Civils de Lyon, Pierre Wertheimer Neurological Hospital, Hôpital Neurologique Pierre Wertheimer, Service de Neurologie C - Hospices Civils de Lyon, NS-Park/F-CRIN, 69677, Bron, France.
Mikail NourredineDepartment of Biostatistics, University Hospital of Lyon, Lyon, France.
Philippe BoulinguezLyon Neuroscience Research Centre, INSERM, University of Lyon, 69622, Lyon, France.
Carole DhelensPharmacy, FRIPHARM, Edouard Herriot Hospital, Lyon University Hospital, Lyon, France.
Bénédicte BallangerLyon Neuroscience Research Centre, INSERM, University of Lyon, 69622, Lyon, France.
Stéphane PrangeDepartment of Neurology C, Expert Parkinson Centre, Hospices Civils de Lyon, Pierre Wertheimer Neurological Hospital, Hôpital Neurologique Pierre Wertheimer, Service de Neurologie C - Hospices Civils de Lyon, NS-Park/F-CRIN, 69677, Bron, France.
Sylvie BinPublic Health Center, Research and Clinical Epidemiology, University Hospital of Lyon, Lyon, France.
Stéphane ThoboisDepartment of Neurology C, Expert Parkinson Centre, Hospices Civils de Lyon, Pierre Wertheimer Neurological Hospital, Hôpital Neurologique Pierre Wertheimer, Service de Neurologie C - Hospices Civils de Lyon, NS-Park/F-CRIN, 69677, Bron, France.
Hospices Civils de Lyon · FRUniversité Claude Bernard Lyon 1 · FRCentre Hospitalier Universitaire de Clermont-Ferrand · FRCentre Hospitalier Universitaire de Saint-Étienne · FRCentre Hospitalier Universitaire de Grenoble · FRCentre Hospitalier Universitaire de Nice · FRCentre National de la Recherche Scientifique · FRLyon College · US

Funding

Ministère de l'Enseignement Supérieur et de la Recherche PHRC interrégional
6 · The paper itself

Abstract

backgroundImpulse control disorders (ICDs) are frequently encountered in Parkinson's disease (PD).

objectivesWe aimed to assess whether clonidine, an α2-adrenergic receptor agonist, would improve ICDs.

methodsWe conducted a multicentre trial in five movement disorder departments. Patients with PD and ICDs (n = 41) were enrolled in an 8-week, randomised (1:1), double-blind, placebo-controlled study of clonidine (75 μg twice a day). Randomisation and allocation to the trial group were carried out by a central computer system. The primary outcome was the change at 8 weeks in symptom severity using the Questionnaire for Impulsive-Compulsive Disorders in Parkinson's Disease-Rating Scale (QUIP-RS) score. A reduction of the most elevated subscore of the QUIP-RS of more than 3 points without any increase in the other QUIP-RS dimension defined success.

resultsBetween 15 May 2019 and 10 September 2021, 19 patients in the clonidine group and 20 patients in the placebo group were enrolled. The proportion difference of success in reducing QUIP-RS at 8 weeks, was 7% (one-sided upper 90% CI 27%) with 42.1% of success in the clonidine group and 35.0% in the placebo group. Compared to patients in the placebo group, patients in the clonidine group experienced a greater reduction in the total QUIP-RS score at 8 weeks (11.0 points vs. 3.6). DISCUSSION: Clonidine was well tolerated but our study was not enough powerful to demonstrate significant superiority compared to placebo in reducing ICDs despite a greater reduction of total QUIP score at 8 weeks. A phase 3 study should be conducted.

trial registrationThe study was registered (NCT03552068) on clinicaltrials.gov on June 11, 2018.

Indexed as

Disruptive, Impulse Control, and Conduct DisordersParkinson DiseaseClonidineDouble-Blind MethodHumansImpulsive BehaviorTreatment OutcomeClonidineClonidineImpulse control disorderNoradrenergic systemParkinson’s diseaseQUIP-RS

Identifiers

PMID37338615
PMCPMC10511565
OpenAlexW4381248158

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.